Ten hospitals, $2.8 billion, zero private equity: who bought the Community Health Systems divestiture book

The deal table

First chart is the bird's-eye view: every completed CHS hospital divestiture since January 2023, plotted by close date and disclosed price, color-coded by the kind of nonprofit on the buy side.

Two patterns jump out. First, the disclosed prices trend upward as the cycle progresses: the 2023 cluster sits near $85-294M, while 2025-2026 deals span $110-623M, including the cycle's single largest transaction (Vanderbilt paying $623M for Tennova Clarksville, closed February 2026). Second, there is no fourth color on this chart. Every dot is one of the three nonprofit categories. Deal-by-deal detail, with each row linking to the source 8-K:

Sum of disclosed closing prices across the ten hospital deals: $2.80 billion. A separate non-hospital divestiture (CHS's ambulatory outreach laboratory services across 13 states) closed December 2025 for $195 million, sold to Labcorp. We exclude that from the hospital deal table because the buyer is a for-profit and the asset isn't a hospital; including it would push the cycle total to roughly $3.0 billion.

Announced but not closed

Two material divestitures CHS announced in this window never closed as filed. Both are worth surfacing because they explain plot twists in the main table, and because "deal terminated" does not always mean "status quo preserved" for the community on the receiving end.

The Novant termination is the more instructive of the two: the deal cleared the boards but lost at the FTC. Lake Norman ultimately re-cleared the same boards with Duke as buyer ($284M for the single hospital, vs the original $320M for Lake Norman plus Davis Regional as a package). Davis Regional was not part of the Duke transaction. The lesson for diligence teams: 8-K filings do not equal closed transactions, and a repriced deal often has a different scope than the original.

Who actually bought

Same data, different question: how does the $2.80 billion in closed proceeds split across buyer type?

Zero private-equity buyers. Zero for-profit hospital operators. The only for-profit transaction in the cycle is the Labcorp lab carveout, which is a different asset class entirely.

The pattern that matters for diligence teams: the buyers are adjacent. Vanderbilt sits 50 miles from Tennova Clarksville. Huntsville Hospital is in the same metro as Crestwood Medical Center. Duke and Lake Norman both serve the Charlotte metro. Tampa General and Bravera Health overlap directly on the Tampa-Brooksville corridor. Freeman Health is the dominant operator in Southwest Missouri and Northwest Arkansas. Every nonprofit buyer bought into a service area they already operate. Pricing cleared because the synergy case writes itself.

Topline and debt

Zooming out to the issuer level: the divestiture program reads as deleveraging, not wind-down. Same-store revenue at the retained hospitals is holding the topline roughly flat even as the chain has shed assets.

Three things to notice. First, revenue has held roughly flat near $12.5 billion since 2020 even as the asset base shrank from $15.6 billion (FY2019) to $13.2 billion (FY2025). Second, long-term debt is down $3.0 billion over the period, a 22 percent reduction. Third, stockholders' equity has been negative every year going back to at least 2019, sitting at -$1.39 billion at fiscal year-end 2025.

The FY2025 net income spike to +$509 million is largely gain-on-sale from the year's closed divestitures, not operating recovery. Operating margin in FY2025 came in at 11.9 percent, the best year in the period, but the underlying same-store operating posture in the retained book has been in the 4 to 8 percent operating-margin band in most quarters.

The $600 million kicker

On April 22, 2026, three weeks after closing the Crestwood-to-Huntsville Hospital sale and two months after closing Tennova Clarksville to Vanderbilt, CHS launched a cash tender offer for up to $600 million of two specific secured notes: the 4.750 percent senior secured notes due 2031 and the 10.875 percent senior secured notes due 2032. The May 6, 2026 early-tender results 8-K reported $994 million of the 2031 notes (94 percent of the issue) and $822 million of the 2032 notes (46 percent of the issue) were validly tendered.

Demand exceeded supply on both tranches. After proration, roughly $600 million of secured debt actually retires. The 10.875 percent coupon on the 2032s is the most expensive money on the CHS balance sheet. That tender is the through-line: divestiture proceeds in, highest-coupon secured debt out, all in the same quarter the deals close.

For analysts modeling CYH forward interest expense, the tender mechanics matter more than the headline divestiture proceeds. Retiring $600 million at a 10.875 percent weighted coupon takes $65 million of annual interest expense out of the run-rate. That is the deleveraging payoff that has not yet shown up in the consensus EPS deck.

What's left

The June 1, 2026 8-K accompanying the Arkansas closing states CHS's post-Arkansas footprint at 60 affiliated hospitals with more than 8,000 beds, operating more than 800 sites of care in 32 distinct markets across 12 states. That is the authoritative number as of June 1, 2026.

Our hospital screener (CMS HCRIS plus the CMS provider ownership overlay) has confirmed CCNs on 11 of those 60 hospitals as of FY2024, totaling 1,559 beds and $1.58 billion in net patient revenue. The 11 cluster in three states (AL, MS, TX). The Mississippi cluster, seven facilities trading under the Merit Health brand, is the obvious next package deal: small enough that a single regional nonprofit could absorb the block, large enough that the Merit Health brand goodwill has real value, and geographically contiguous enough to clear antitrust review.

The standout in the confirmed eleven is Laredo Medical Center in Texas. FY2024 net patient revenue of $373 million on 289 beds, with a 33 percent operating margin. For context, the median FY2024 operating margin across the entire HCRIS acute-care universe was roughly 2 to 4 percent. Laredo is materially over-earning. If CHS continues divesting through 2027, Laredo and the larger Texas asset (Longview Regional, $328 million FY2024 revenue on 224 beds, 9.2 percent operating margin) are the obvious premium-price candidates.

The bottom of the same eleven looks different. Grove Hill Memorial in Alabama posted a -53.7 percent operating margin in FY2024, with discharges down 63 percent year-over-year. On the financial comp set, that is not a marketable asset.

It is also one of the few hospitals serving Clarke County, AL, a rural community of roughly 24,000 residents. The financial conclusion (closure candidate) sits next to a service-area question (what happens to emergency response time and obstetric access if Grove Hill closes) that the comp set does not answer. Both sides of that question are worth holding when modeling the back half of the divestiture cycle.

What it means

None of the three workflows above is exotic. They are the standard PE diligence, nonprofit M&A, and HY credit workflows that have run for decades. The constraint was always assembling the per-deal table, the buyer classification, the topline and debt trajectory, and the forward-tender mechanics into one view. That used to take an analyst week. The version you just read took 30 minutes.

Closing

There is no scandal in this post. CHS disclosed each transaction in the proper 8-K, with the closing 8-K filed in the proper window, with the financial advisor listed where required. Every buyer named here is a real operator with a real strategic reason to bid. The divestiture program is doing exactly what management said it would do, at prices the market is willing to clear, to buyers the consensus narrative did not predict.

The reason this analysis is worth publishing is that the consensus narrative is still wrong. Trade-press coverage of CHS divestitures has framed buyer-after-buyer as individually surprising. Read together as a cohort, the pattern is unmistakable and structural. Regional nonprofits and academic systems are the bid for publicly-traded for-profit hospital exits in markets where the buyer already has an operating presence. They pay full prices. They use named bankers. They close on the disclosed schedule.

The next CHS quarterly call is in late July 2026. Management is likely to disclose the size of the next divestiture pipeline at that point. The same query rerun against the next cycle's filings will surface the next round of buyers within a week of the 8-Ks hitting EDGAR. The communities on the receiving end of those deals deserve the same attention as the deal multiples.